Literature DB >> 10491320

Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes.

H Okuda1, S Hirai, Y Takaki, M Kamada, M Baba, N Sakai, T Kishida, S Kaneko, M Yao, S Ohno, T Shuin.   

Abstract

VHL tumor suppressor protein contains two domains, alpha and beta. The alpha-domain is involved in the formation of a large protein complex suggested to be involved in ubiquitin-mediated protein degradation. However, the role of the beta-domain, which may recognize the target proteins for protein degradation, remains unknown. Here we report that the beta-domain interacts directly with atypical PKC isotypes, PKCzeta and PKClambda. Further, the regulatory domain of aPKC is sufficient for this direct protein-protein interaction. Since aPKC isotypes have been implicated in the regulation of cell growth and apoptosis, these results suggest that aPKC isotypes are potential direct target of the VHL beta-domain. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10491320     DOI: 10.1006/bbrc.1999.1347

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

1.  Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein.

Authors:  Eijiro Nakamura; Paula Abreu-e-Lima; Yasuo Awakura; Takahiro Inoue; Toshiyuki Kamoto; Osamu Ogawa; Hirokazu Kotani; Toshiaki Manabe; Guo-Jun Zhang; Keiichi Kondo; Vānia Nosé; William G Kaelin
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

Review 2.  Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.

Authors:  Johannes Schödel; Steffen Grampp; Eamonn R Maher; Holger Moch; Peter J Ratcliffe; Paul Russo; David R Mole
Journal:  Eur Urol       Date:  2015-08-19       Impact factor: 20.096

3.  The von Hippel-Lindau tumour-suppressor protein interaction with protein kinase Cdelta.

Authors:  Xavier Iturrioz; Joanne Durgan; Véronique Calleja; Banafshé Larijani; Heiwa Okuda; Richard Whelan; Peter J Parker
Journal:  Biochem J       Date:  2006-07-01       Impact factor: 3.857

4.  HOIL-1L functions as the PKCζ ubiquitin ligase to promote lung tumor growth.

Authors:  Markus A Queisser; Laura A Dada; Nimrod Deiss-Yehiely; Martin Angulo; Guofei Zhou; Fotini M Kouri; Lawrence M Knab; Jing Liu; Alexander H Stegh; Malcolm M DeCamp; G R Scott Budinger; Navdeep S Chandel; Aaron Ciechanover; Kazuhiro Iwai; Jacob I Sznajder
Journal:  Am J Respir Crit Care Med       Date:  2014-09-15       Impact factor: 21.405

Review 5.  Role of VHL gene mutation in human renal cell carcinoma.

Authors:  Wani Arjumand; Sarwat Sultana
Journal:  Tumour Biol       Date:  2011-11-29

6.  N-myc downstream-regulated gene 1 (NDRG1) a differentiation marker of human breast cancer.

Authors:  Abbas Fotovati; Samah Abu-Ali; Masayoshi Kage; Kazuo Shirouzu; Hideaki Yamana; Michihiko Kuwano
Journal:  Pathol Oncol Res       Date:  2011-01-09       Impact factor: 3.201

7.  EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance.

Authors:  Shuijie Li; Javier Rodriguez; Wenyu Li; Petra Bullova; Stuart M Fell; Olga Surova; Isabelle Westerlund; Danijal Topcic; Maria Bergsland; Adam Stenman; Jonas Muhr; Monica Nistér; Johan Holmberg; C Christofer Juhlin; Catharina Larsson; Alex von Kriegsheim; William G Kaelin; Susanne Schlisio
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-02       Impact factor: 11.205

8.  Adenylate cyclase regulates elongation of mammalian primary cilia.

Authors:  Young Ou; Yibing Ruan; Min Cheng; Joanna J Moser; Jerome B Rattner; Frans A van der Hoorn
Journal:  Exp Cell Res       Date:  2009-07-02       Impact factor: 3.905

Review 9.  VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment.

Authors:  W Kimryn Rathmell; Shufen Chen
Journal:  Expert Rev Anticancer Ther       Date:  2008-01       Impact factor: 4.512

10.  Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.

Authors:  Valentina Bangiyeva; Ava Rosenbloom; Ashlynn E Alexander; Bella Isanova; Timothy Popko; Alan R Schoenfeld
Journal:  BMC Cancer       Date:  2009-07-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.